Ubiquitin signaling in cell cycle control and tumorigenesis.


Journal

Cell death and differentiation
ISSN: 1476-5403
Titre abrégé: Cell Death Differ
Pays: England
ID NLM: 9437445

Informations de publication

Date de publication:
02 2021
Historique:
received: 07 07 2020
accepted: 12 10 2020
revised: 08 10 2020
pubmed: 2 11 2020
medline: 16 12 2021
entrez: 1 11 2020
Statut: ppublish

Résumé

Cell cycle progression is a tightly regulated process by which DNA replicates and cell reproduces. The major driving force underlying cell cycle progression is the sequential activation of cyclin-dependent kinases (CDKs), which is achieved in part by the ubiquitin-mediated proteolysis of their cyclin partners and kinase inhibitors (CKIs). In eukaryotic cells, two families of E3 ubiquitin ligases, anaphase-promoting complex/cyclosome and Skp1-Cul1-F-box protein complex, are responsible for ubiquitination and proteasomal degradation of many of these CDK regulators, ensuring cell cycle progresses in a timely and precisely regulated manner. In the past couple of decades, accumulating evidence have demonstrated that the dysregulated cell cycle transition caused by inefficient proteolytic control leads to uncontrolled cell proliferation and finally results in tumorigenesis. Based upon this notion, targeting the E3 ubiquitin ligases involved in cell cycle regulation is expected to provide novel therapeutic strategies for cancer treatment. Thus, a better understanding of the diversity and complexity of ubiquitin signaling in cell cycle regulation will shed new light on the precise control of the cell cycle progression and guide anticancer drug development.

Identifiants

pubmed: 33130827
doi: 10.1038/s41418-020-00648-0
pii: 10.1038/s41418-020-00648-0
pmc: PMC7862229
doi:

Substances chimiques

Cell Cycle Proteins 0
Ubiquitin 0
Anaphase-Promoting Complex-Cyclosome EC 2.3.2.27
Ubiquitin-Protein Ligases EC 2.3.2.27
Cyclin-Dependent Kinases EC 2.7.11.22

Types de publication

Journal Article Research Support, N.I.H., Extramural Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

427-438

Subventions

Organisme : NCI NIH HHS
ID : R01 CA200651
Pays : United States

Références

Weinberg RA. The Retinoblastoma protein and cell cycle control. Cell. 1995;81:323–30.
pubmed: 7736585 doi: 10.1016/0092-8674(95)90385-2
Zarkowska T, Mittnach S. Differential phosphorylation of the Retinoblastoma protein by G1/S cyclin-dependent kinases. J Biol Chem. 1997;272:12738–46.
pubmed: 9139732 doi: 10.1074/jbc.272.19.12738
Hinds PW, Mittnacht S, Dulic V, Arnold A, Reed SI, Weinberg RA. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell. 1992;70:993–1006.
pubmed: 1388095 doi: 10.1016/0092-8674(92)90249-C
Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G. Cyclin A is required at two points in the human cell cycle. EMBO J. 1992;11:961–71.
pubmed: 1312467 pmcid: 556537 doi: 10.1002/j.1460-2075.1992.tb05135.x
Petersen BO, Lukas J, Sørensen CS, Bartek J, Helin K. Phosphorylation of mammalian CDC6 by cyclin A/CDK2 regulates its subcellular localization. EMBO J. 1999;18:396–410.
pubmed: 9889196 pmcid: 1171134 doi: 10.1093/emboj/18.2.396
Furuno N, Elzen ND, Pines J. Human cyclin A is required for mitosis until mid prophase. J Cell Biol. 1999;147:295–306.
pubmed: 10525536 pmcid: 2174228 doi: 10.1083/jcb.147.2.295
Boer LD, Oakes V, Beamish H, Giles N, Stevens F, Torres MS, et al. Cyclin A/cdk2 coordinates centrosomal and nuclear mitotic events. Oncogene. 2008;27:4261–8.
pubmed: 18372919 doi: 10.1038/onc.2008.74
Vigneron S, Sundermann L, LabbéJC, Pintard L, Radulescu O, Castro A, et al. Cyclin A-cdk1-dependent phosphorylation of Bora is the triggering factor promoting mitotic entry. Dev Cell. 2018;45:637–50.
pubmed: 29870721 doi: 10.1016/j.devcel.2018.05.005
Lindqvist A, Zon WV, Rosenthal CK, Wolthuls RM. Cyclin B1-Cdk1 activation continues after centrosome separation to control mitotic progression. PLoS Biol. 2007;5:e123. https://doi.org/10.1371/journal.pbio.0050123.
doi: 10.1371/journal.pbio.0050123. pubmed: 17472438 pmcid: 1858714
Ferrero M, Ferragud J, Orlando L, Valero L, Pino MS, Farràs R, et al. Phosphorylation of AIB1 at mitosis is regulated by CDK1/Cyclin B. PLoS ONE. 2011;6:e28602. https://doi.org/10.1371/journal.pone.0028602.
doi: 10.1371/journal.pone.0028602. pubmed: 22163316 pmcid: 3233587
Guo L, Mohd KS, Ren H, Xin G, Jiang Q, Clarke PR, et al. Phosphorylation of importin-alpha1 by CDK1-Cyclin B1 controls mitotic spindle assembly. J Cell Sci. 2019;132:jcs232314. https://doi.org/10.1242/jcs.232314.
doi: 10.1242/jcs.232314. pubmed: 31434716 pmcid: 6765185
Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13:1501–12.
pubmed: 10385618 doi: 10.1101/gad.13.12.1501
Glotzer M, Murray AW, Kirschner MW. Cyclin is degraded by the ubiquitin pathway. Nature. 1991;349:132–8.
pubmed: 1846030 doi: 10.1038/349132a0
Nakayama K, Nagahama H, Minamishima YA, Miyake S, Ishida N, Hatakeyama S, et al. Skp2-mediated degradation of p27 regulates progression into mitosis. Dev Cell. 2004;6:661–72.
pubmed: 15130491 doi: 10.1016/S1534-5807(04)00131-5
Tomoda K, Kubota Y, Kato J. Degradation of the cyclin-dependent-kinase inhibitor p27
pubmed: 10086358 doi: 10.1038/18230
Bloom J, Amador V, Bartolini F, DeMartino G, Pagano M. Proteasome-mediated degradation of p21 via N-terminal ubiquitinylation. Cell. 2003;115:71–82.
pubmed: 14532004 doi: 10.1016/S0092-8674(03)00755-4
Hershko A. Roles of ubiquitin-mediated proteolysis in cell cycle control. Curr Opin Cell Biol. 1997;9:788–99.
pubmed: 9425343 doi: 10.1016/S0955-0674(97)80079-8
Nakayama KI, Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer. 2006;6:369–81.
pubmed: 16633365 doi: 10.1038/nrc1881
Goldstein G, Scheid M, Hammerling U, Schlesinger DH, Niall HD, Boyse EA. Isolation of a polypeptide that has lymphocyte-differentiating properties and is probably represented universally in living cells. Proc Natl Acad Sci USA. 1975;72:11–5.
pubmed: 1078892 doi: 10.1073/pnas.72.1.11 pmcid: 432229
Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem. 1998;67:425–79.
pubmed: 9759494 doi: 10.1146/annurev.biochem.67.1.425
Matsumoto ML, Wickliffe KE, Dong KC, Yu C, Bosanac I, Bustos D. K11-linked polyubiquitination in cell cycle control revealed by a K11 linkage-specific antibody. Mol Cell. 2010;39:477–84.
pubmed: 20655260 doi: 10.1016/j.molcel.2010.07.001
Wickliffe KE, Williamson A, Meyer HJ, Kelly A, Rape M. K11-linked ubiquitin chains as novel regulators of cell division. Trends Cell Biol. 2011;21:656–63.
pubmed: 21978762 pmcid: 3205209 doi: 10.1016/j.tcb.2011.08.008
Grice GL, Nathan JA. The recognition of ubiquitinated proteins by the proteasome. Cell Mol Life Sci. 2016;73:3497–506.
pubmed: 27137187 pmcid: 4980412 doi: 10.1007/s00018-016-2255-5
Emmerich CH, Schmukle AC, Walczak H. The emerging role of linear ubiquitination in cell signaling. Sci Signal. 2011;4:re5. https://doi.org/10.1126/scisignal.2002187.
doi: 10.1126/scisignal.2002187. pubmed: 22375051
Akutsu M, Dikic I, Bremm A. Ubiquitin chain diversity at a glance. J Cell Sci. 2016;129:875–80.
pubmed: 26906419 doi: 10.1242/jcs.183954
Swatek KN, Komander D. Ubiquitin modifications. Cell Res. 2016;26:399–422.
pubmed: 27012465 pmcid: 4822133 doi: 10.1038/cr.2016.39
Suryadinata R, Sadowski M, Sarcevic B. Control of cell cycle progression by phosphorylation of cyclin-dependent kinase (CDK) substrates. Biosci Rep. 2010;30:243–55.
pubmed: 20337599 doi: 10.1042/BSR20090171
Swaffer MP, Jones AW, Flynn HR, Snijders A, Nurse P. CDK substrate phosphorylation and ordering the cell cycle. Cell. 2016;167:1750–61.
pubmed: 27984725 pmcid: 5161751 doi: 10.1016/j.cell.2016.11.034
Obaya AJ, Sedivy JM. Regulation of cyclin-Cdk activity in mammalian cells. Cell Mol Life Sci. 2002;59:126–42.
pubmed: 11846025 doi: 10.1007/s00018-002-8410-1
Vodermaier HC. APC/C and SCF: controlling each other and the cell cycle. Curr Biol. 2004;14:R787–96.
pubmed: 15380093 doi: 10.1016/j.cub.2004.09.020
Barford D. Structure, function and mechanism of the anaphase promoting complex (APC/C). Q Rev Biophys. 2011;44:153–90.
pubmed: 21092369 doi: 10.1017/S0033583510000259
Zhang J, Wan L, Dai X, Sun Y, Wei W. Functional characterization of anaphase promoting complex/cyclosome (APC/C) E3 ubiquitin ligases in tumorigenesis. Biochim Biophys Acta. 2014;1845:277–93.
pubmed: 24569229 pmcid: 3995847
Qiao R, Weissmann F, Yamaguchi M, Brown NG, VanderLinden R, Imre R, et al. Mechanism of APC/C
pubmed: 27114510 doi: 10.1073/pnas.1604929113 pmcid: 4868491
Zhang S, Chang L, Alfieri C, Zhang Z, Yang J, Maslen S, et al. Molecular mechanism of APC/C activation by mitotic phosphorylation. Nature. 2016;533:260–4.
pubmed: 27120157 pmcid: 4878669 doi: 10.1038/nature17973
Chang DC, Xu N, Luo KQ. Degradation of cyclin B is required for the onset of anaphase in mammalian cells. J Biol Chem. 2003;278:37865–73.
pubmed: 12865421 doi: 10.1074/jbc.M306376200
Singleton MR, Uhlmann F. Separase-securin complex: a cunning way to control chromosome segregation. Nat Struct Mol Biol. 2017;24:337–9.
pubmed: 28384135 doi: 10.1038/nsmb.3393
Crasta K, Lim HH, Giddings TH Jr, Winey M, Surana U. Inactivation of Cdh1 by synergistic action of Cdk1 and polo kinase is necessary for proper assembly of the mitotic spindle. Nat Cell Biol. 2008;10:665–75.
pubmed: 18500339 pmcid: 2677644 doi: 10.1038/ncb1729
Visintin R, Craig K, Hwang ES, Prinz S, Tyers M, Amon A. The phosphatase Cdc14 triggers mitotic exit by reversal of Cdk-dependent phosphorylation. Mol Cell. 1998;2:709–18.
pubmed: 9885559 doi: 10.1016/S1097-2765(00)80286-5
Sullivan M, Uhlmann F. A non-proteolytic function of separase links the onset of anaphase to mitotic exit. Nat Cell Biol. 2003;5:249–54.
pubmed: 12598903 pmcid: 2610357 doi: 10.1038/ncb940
Li M, Zhang P. The function of APC/C
Jin J, Cardozo T, Lovering RC, Elledge SJ, Pagano M, Harper JW. Systematic analysis and nomenclature of mammalian F-box proteins. Genes Dev. 2004;18:2573–80.
pubmed: 15520277 pmcid: 525538 doi: 10.1101/gad.1255304
Ang XL, Harper JW. SCF-mediated protein degradation and cell cycle control. Oncogene. 2005;24:2860–70.
pubmed: 15838520 doi: 10.1038/sj.onc.1208614
Nakayama KI, Nakayama K. Regulation of the cell cycle by SCF-type ubiquitin ligases. Semin Cell Dev Biol. 2005;16:323–33.
pubmed: 15840441 doi: 10.1016/j.semcdb.2005.02.010
D’Angiolella V, Esencay M, Pagano M. A cyclin without cyclin-dependent kinases: cyclin F controls genome stability through ubiquitin-mediated proteolysis. Trends Cell Biol. 2013;23:135–40.
pubmed: 23182110 doi: 10.1016/j.tcb.2012.10.011
Bashir T, Dorrello NV, Amador V, Guardavaccaro D, Pagano M. Control of the SCF
pubmed: 15014502 doi: 10.1038/nature02330
Wei W, Ayad NG, Wan Y, Zhang GJ, Kirschner MW, Kaelin WG Jr. Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex. Nature. 2004;428:194–8.
pubmed: 15014503 doi: 10.1038/nature02381
Geneviève R, Coulombe P, Tanguay PL, Boutonnet C, Meloche S. Phosphorylation of Skp2 regulated by CDK2 and Cdc14B protects it from degradation by APCCdh1 in G1 phase. EMBO J. 2008;27:679–91.
doi: 10.1038/emboj.2008.6
Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE. Cyclin E-CDK2 is a regulator of p27
pubmed: 9192873 doi: 10.1101/gad.11.11.1464
Montagnoli A, Fiore F, Eytan E, Carrano AC, Draetta GF, Hershko A, et al. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev. 1999;13:1181–9.
pubmed: 10323868 pmcid: 316946 doi: 10.1101/gad.13.9.1181
Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol. 1999;1:193–9.
pubmed: 10559916 doi: 10.1038/12013
Bornstein G, Bloom J, Sitry-Shevah S, Nakayama K, Pagano M, Hershko A. Role of the SCF
pubmed: 12730199 doi: 10.1074/jbc.M301774200
Kamura T, Hara T, Kotoshiba S, Yada M, Ishida N, Imaki H, et al. Degradation of p57
pubmed: 12925736 doi: 10.1073/pnas.1831009100 pmcid: 193544
Denicourt C, Dowdy SF. Cip/Kip proteins: more than just CDKs inhibitors. Genes Dev. 2004;18:851–5.
pubmed: 15107401 doi: 10.1101/gad.1205304
Nakayama K, Nagahama H, Minamishima YA, Matsumoto M, Nakamichi I, Kitagawa K, et al. Targeted disruption of Skp2 results in accumulation of cyclin E and p27
pubmed: 10790373 pmcid: 305685 doi: 10.1093/emboj/19.9.2069
Clijsters L, Hoencamp C, Calis JJ, Marzio A, Handgraaf SM, Cuitino MC, et al. Cyclin F controls cell-cycle transcriptional outputs by directing the degradation of the three activator E2Fs. Mol Cell. 2019;74:1264–77.
pubmed: 31130363 pmcid: 6588466 doi: 10.1016/j.molcel.2019.04.010
Burdova K, Yang H, Faedda R, Hume S, Chauhan J, Ebner D, et al. E2F1 proteolysis via SCF-cyclin F underlies synthetic lethality between cyclin F loss and Chk1 inhibition. EMBO J. 2019;38:e101443. https://doi.org/10.15252/embj.2018101443.
doi: 10.15252/embj.2018101443. pubmed: 31424118 pmcid: 6792013
Dankert JF, Rona G, Clijsters L, Geter P, Skaar JR, Bermudez-Hernandez K, et al. Cyclin F-mediated degradation of SLBP limits H2A.X accumulation and apoptosis upon genotoxic stress in G2. Mol Cell. 2016;64:507–19.
pubmed: 27773672 pmcid: 5097008 doi: 10.1016/j.molcel.2016.09.010
D’Angiolella V, Donato V, Forrester FM, Jeong YT, Pellacani C, Kudo Y, et al. Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair. Cell. 2012;149:1023–34.
pubmed: 22632967 pmcid: 3616325 doi: 10.1016/j.cell.2012.03.043
D’Angiolella V, Donato V, Vijayakumar S, Saraf A, Florens L, Washburn MP, et al. SCF
pubmed: 20596027 pmcid: 2946399 doi: 10.1038/nature09140
Mavrommati I, Faedda R, Galasso G, Li J, Burdova K, Fischer R, et al. β-TrCP- and casein kinase II-mediated degradation of Cyclin F controls timely mitotic progression. Cell Rep. 2018;24:3404–12.
pubmed: 30257202 pmcid: 6172692 doi: 10.1016/j.celrep.2018.08.076
Li C, Vassilev A, DePamphilis ML. Role for Cdk1(Cdc2)/cyclin A in preventing the mammalian origin recognition complex’s largest subunit (Orc1) from binding to chromatin during mitosis. Mol Cell Biol. 2004;24:5875–86.
pubmed: 15199143 pmcid: 480893 doi: 10.1128/MCB.24.13.5875-5886.2004
Gong D, Ferrell JE Jr. The roles of cyclin A2, B1, and B2 in early and late mitotic events. Mol Biol Cell. 2010;21:3149–61.
pubmed: 20660152 pmcid: 2938381 doi: 10.1091/mbc.e10-05-0393
Abe S, Nagasaka K, Hirayama Y, Kozuka-Hata H, Oyama M, Aoyagi Y, et al. The initial phase of chromosome condensation requires Cdk1-mediated phosphorylation of the CAP-D3 subunit of condensin II. Genes Dev. 2011;25:863–74.
pubmed: 21498573 pmcid: 3078710 doi: 10.1101/gad.2016411
Elzen N, Pines J. Cyclin A is destroyed in prometaphase and can delay chromosome alignment and anaphase. J Cell Biol. 2001;153:121–36.
doi: 10.1083/jcb.153.1.121
Geley S, Kramer E, Gieffers C, Gannon J, Peters JM, Hunt T. Anaphase-promoting complex/cyclosome–dependent proteolysis of human cyclin A starts at the beginning of mitosis and is not subject to the spindle assembly checkpoint. J Cell Biol. 2001;153:137–48.
pubmed: 11285280 pmcid: 2185534 doi: 10.1083/jcb.153.1.137
Hershko A. Mechanisms and regulation of the degradation of cyclin B. Philos Trans R Soc Lond B Biol Sci. 1999;354:1571–75.
pubmed: 10582242 pmcid: 1692665 doi: 10.1098/rstb.1999.0500
Clute P, Pines J. Temporal and spatial control of cyclin B1 destruction in metaphase. Nat Cell Biol. 1999;1:82–7.
pubmed: 10559878 doi: 10.1038/10049
Peters JM. The anaphase-promoting complex: proteolysis in mitosis and beyond. Mol Cell. 2002;9:931–43.
pubmed: 12049731 doi: 10.1016/S1097-2765(02)00540-3
Wolthuis R, Clay-Farrace L, Zon W, Yekezare M, Koop L, Ogink J, et al. Cdc20 and Cks direct the spindle checkpoint-independent destruction of cyclin A. Mol Cell. 2008;30:290–302.
pubmed: 18471975 doi: 10.1016/j.molcel.2008.02.027
Fang G, Yu H, Kirschner MW. The checkpoint protein MAD2 and the mitotic regulator CDC20 form a ternary complex with the anaphase-promoting complex to control anaphase initiation. Genes Dev. 1998;12:1871–83.
pubmed: 9637688 pmcid: 316912 doi: 10.1101/gad.12.12.1871
Michel L, Diaz-Rodriguez E, Narayan G, Hernando E, Murty V, Benezra R. Complete loss of the tumor suppressor MAD2 causes premature cyclin B degradation and mitotic failure in human somatic cells. Proc Natl Acad Sci USA. 2004;101:4459–64.
pubmed: 15070740 doi: 10.1073/pnas.0306069101 pmcid: 384769
Rossi M, Duan S, Jeong YT, Horn M, Saraf A, Florens L, et al. Regulation of the CRL4
pubmed: 23478441 pmcid: 3624904 doi: 10.1016/j.molcel.2013.02.004
Fukushima H, Ogura K, Wan L, Lu Y, Li V, Gao D, et al. SCF-mediated Cdh1 degradation defines a negative feedback system that coordinates cell-cycle progression. Cell Rep. 2013;4:803–16.
pubmed: 23972993 doi: 10.1016/j.celrep.2013.07.031
Choudhury R, Bonacci T, Arceci A, Lahiri D, Mills CA, Kernan JL, et al. APC/C and SCF
pubmed: 27653696 pmcid: 5111906 doi: 10.1016/j.celrep.2016.08.058
Watanabe N, Arai H, Nishihara Y, Taniguchi M, Watanabe N, Hunter T, et al. M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCF
pubmed: 15070733 doi: 10.1073/pnas.0307700101 pmcid: 384762
Peschiaroli A, Dorrello NV, Guardavaccaro D, Venere M, Halazonetis T, Sherman NE, et al. SCF
pubmed: 16885022 doi: 10.1016/j.molcel.2006.06.013
Margottin-Goguet F, Hsu JY, Loktev A, Hsieh HM, Reimann J, Jackson PK. Prophase destruction of Emi1 by the SCF
pubmed: 12791267 doi: 10.1016/S1534-5807(03)00153-9
Busino L, Donzelli M, Chiesa M, Guardavaccaro D, Ganoth D, Dorrello NV, et al. Degradation of Cdc25A by β-TrCP during S phase and in response to DNA damage. Nature. 2003;426:87–91.
pubmed: 14603323 doi: 10.1038/nature02082
Guardavaccaro D, Kudo Y, Boulaire J, Barchi M, Busino L, Donzelli M, et al. Control of meiotic and mitotic progression by the F box protein β-Trcp1 in vivo. Dev Cell. 2003;4:799–812.
pubmed: 12791266 doi: 10.1016/S1534-5807(03)00154-0
Guardavaccaro D, Frescas D, Dorrello NV, Peschiaroli A, Multani AS, Cardozo T, et al. Control of chromosome stability by the β-TrCP-REST-Mad2 axis. Nature. 2008;452:365–9.
pubmed: 18354482 pmcid: 2707768 doi: 10.1038/nature06641
Cardozo T, Pagano M. The SCF ubiquitin ligase: insights into a molecular machine. Nat Rev Mol Cell Biol. 2004;5:739–51.
pubmed: 15340381 doi: 10.1038/nrm1471
Jin J, Shirogane T, Xu L, Nalepa G, Qin J, Elledge SJ, et al. SCFβ-TRCP links Chk1 signaling to degradation of the Cdc25A protein phosphatase. Genes Dev. 2003;17:3062–74.
pubmed: 14681206 pmcid: 305258 doi: 10.1101/gad.1157503
Xiao Z, Chen Z, Gunasekera AH, Sowin TJ, Rosenberg SH, Fesik S, et al. Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents. J Biol Chem. 2003;278:21767–73.
pubmed: 12676925 doi: 10.1074/jbc.M300229200
Busino L, Chiesa M, Draetta GF, Donzelli M. Cdc25A phosphatase-combinatorial phosphorylation, ubiquitylation and proteolysis. Oncogene. 2004;23:2050–6.
pubmed: 15021892 doi: 10.1038/sj.onc.1207394
Marzio A, Puccini J, Kwon Y, Maverakis NK, Arbini A, Sung P, et al. The F-box domain-dependent activity of EMI1 regulates PARPi sensitivity in triple-negative breast cancers. Mol Cell. 2019;73:224–37.
pubmed: 30554948 doi: 10.1016/j.molcel.2018.11.003
Cui D, Xiong X, Shu J, Dai X, Sun Y, Zhao Y. FBXW7 confers radiation survival by targeting p53 for degradation. Cell Rep. 2020;30:497–509.
pubmed: 31940492 doi: 10.1016/j.celrep.2019.12.032
Uckelmann M, Sixma TK. Histone ubiquitination in the DNA damage response. DNA Repair. 2017;56:92–101.
pubmed: 28624371 doi: 10.1016/j.dnarep.2017.06.011
Joo HY, Zhai L, Yang C, Nie S, Erdjument-Bromage H, Tempst P, et al. Regulation of cell cycle progression and gene expression by H2A deubiquitination. Nature. 2007;449:1068–72.
pubmed: 17914355 doi: 10.1038/nature06256
Lara-Gonzalez P, Westhorpe FG, Taylor SS. The spindle assembly checkpoint. Curr Biol. 2012;22:R966–80.
pubmed: 23174302 doi: 10.1016/j.cub.2012.10.006
Varshavsky A. Naming a targeting signal. Cell. 1991;64:13–5.
pubmed: 1986863 doi: 10.1016/0092-8674(91)90202-A
Pfleger CM, Kirschner MW. The KEN box- an APC recognition signal distinct from the D box targeted by Cdh1. Genes Dev. 2000;14:655–65.
pubmed: 10733526 pmcid: 316466
Fiore BD, Davey NE, Hagting A, Izawa D, Mansfeld J, Gibson TJ, et al. The ABBA motif binds APC/C activators and is shared by APC/C substrates and regulators. Dev Cell. 2015;32:358–72.
pubmed: 25669885 pmcid: 4713905 doi: 10.1016/j.devcel.2015.01.003
Skaar JR, Pagan JK, Pagano M. Mechanisms and function of substrate recruitment by F-box proteins. Nat Rev Mol Cell Biol. 2013;14:369–81.
pubmed: 23657496 doi: 10.1038/nrm3582
Fuchs SY, Spiegelman VS, Kumar KG. The many faces of β-TrCP E3 ubiquitin ligases: reflections in the magic mirror of cancer. Oncogene. 2004;23:2028–36.
pubmed: 15021890 doi: 10.1038/sj.onc.1207389
Reimann JD, Freed E, Hsu JY, Kramer ER, Peters JM, Jackson PK. Emi1 is a mitotic regulator that interacts with Cdc20 and inhibits the anaphase promoting complex. Cell. 2001;105:645–55.
pubmed: 11389834 doi: 10.1016/S0092-8674(01)00361-0
Cheng Y, Li G. Role of the ubiquitin ligase Fbw7 in cancer progression. Cancer Metastasis Rev. 2012;31:75–87.
pubmed: 22124735 doi: 10.1007/s10555-011-9330-z
Koepp DM, Schaefer LK, Ye X, Keyomarsi K, Chu C, Harper JW, et al. Phosphorylation-dependent ubiquitination of cyclin E by the SCF
pubmed: 11533444 doi: 10.1126/science.1065203
Ye X, Nalepa G, Welcker M, Kessler BM, Spooner E, Qin J, et al. Recognition of phosphodegron motifs in human cyclin E by the SCF
pubmed: 15364936 doi: 10.1074/jbc.M409226200
Hao B, Zheng N, Schulman BA, Wu G, Miller JJ, Pagano M, et al. Structural basis of the Cks1-dependent recognition of p27
pubmed: 16209941 doi: 10.1016/j.molcel.2005.09.003
Smolders L, Teodoro JG. Targeting the anaphase promoting complex: common pathways for viral infection and cancer therapy. Expert Opin Ther Targets. 2011;15:767–80.
pubmed: 21375465 doi: 10.1517/14728222.2011.558008
Hornig N, Knowles PP, McDonald NQ, Uhlmann F. The dual mechanism of separase regulation by securin. Curr Biol. 2002;12:973–82.
pubmed: 12123570 doi: 10.1016/S0960-9822(02)00847-3
Li M, York JP, Zhang P. Loss of Cdc20 causes a securin-dependent metaphase arrest in two-cell mouse embryos. Mol Cell Biol. 2007;27:3481–8.
pubmed: 17325031 pmcid: 1899968 doi: 10.1128/MCB.02088-06
Manchado E, Guillamot M, Càrcer G, Eguren M, Trickey M, García-Higuera I, et al. Targeting mitotic exit leads to tumor regression in vivo: modulation by Cdk1, Mastl, and the PP2A/B55α, δ phosphatase. Cancer Cell. 2010;18:641–54.
pubmed: 21156286 doi: 10.1016/j.ccr.2010.10.028
Li M, Fang X, Wei Z, York JP, Zhang P. Loss of spindle assembly checkpoint-mediated inhibition of Cdc20 promotes tumorigenesis in mice. J Cell Biol. 2009;185:983–94.
pubmed: 19528295 pmcid: 2711613 doi: 10.1083/jcb.200904020
Wang Z, Wan L, Zhong J, Inuzuka H, Liu P, Sarkar FH, et al. Cdc20: a potential novel therapeutic target for cancer treatment. Curr Pharm Des. 2013;19:3210–4.
pubmed: 23151139 pmcid: 4014638 doi: 10.2174/1381612811319180005
García-Higuera I, Manchado E, Dubus P, Cañamero M, Méndez J, Moreno S, et al. Genomic stability and tumour suppression by the APC/C cofactor Cdh1. Nat Cell Biol. 2008;10:802–11.
pubmed: 18552834 doi: 10.1038/ncb1742
Frescas D, Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and β-TrCP: tipping the scales of cancer. Nat Rev Cancer. 2008;8:438–49.
pubmed: 18500245 pmcid: 2711846 doi: 10.1038/nrc2396
Welcker M, Clurman BE. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer. 2008;8:83–93.
pubmed: 18094723 doi: 10.1038/nrc2290
Wang Z, Liu P, Inuzuka H, Wei W. Roles of F-box proteins in cancer. Nat Rev Cancer. 2014;14:233–47.
pubmed: 24658274 pmcid: 4306233 doi: 10.1038/nrc3700
Gstaiger M, Jordan R, Lim M, Catzavelos C, Mestan J, Slingerland J, et al. Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci USA. 2001;98:5043–8.
pubmed: 11309491 doi: 10.1073/pnas.081474898 pmcid: 33160
Bhattacharya S, Garriga J, Calbó J, Yong T, Haines DS, Graña X. SKP2 associates with p130 and accelerates p130 ubiquitylation and degradation in human cells. Oncogene. 2003;22:2443–51.
pubmed: 12717421 doi: 10.1038/sj.onc.1206339
Li X, Zhao Q, Liao R, Sun P, Wu X. The SCF
pubmed: 12840033 doi: 10.1074/jbc.C300251200
Chan C, Morrow JK, Li C, Gao Y, Jin G, Moten A, et al. Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell. 2013;154:556–68.
pubmed: 23911321 doi: 10.1016/j.cell.2013.06.048
Minella AC, Welcker M, Clurman BE. Ras activity regulates cyclin E degradation by the Fbw7 pathway. Proc Natl Acad Sci USA. 2005;102:9649–54.
pubmed: 15980150 doi: 10.1073/pnas.0503677102 pmcid: 1172263
Welcker M, Orian A, Jin J, Grim JE, Harper JW, Eisenman RN, et al. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci USA. 2004;101:9085–90.
pubmed: 15150404 doi: 10.1073/pnas.0402770101 pmcid: 428477
Dang CV. MYC on the path to cancer. Cell. 2012;149:22–35.
pubmed: 22464321 pmcid: 3345192 doi: 10.1016/j.cell.2012.03.003
Do K, Doroshow JH, Kummar S. Wee1 kinase as a target for cancer therapy. Cell Cycle. 2013;12:3159–64.
pubmed: 24013427 pmcid: 3865011 doi: 10.4161/cc.26062
Cangi MG, Cukor B, Soung P, Signoretti S, Moreira G Jr, Ranashinge M, et al. Role of the Cdc25A phosphatase in human breast cancer. J Clin Invest. 2000;106:753–61.
pubmed: 10995786 pmcid: 381390 doi: 10.1172/JCI9174
Tsai W, Chung YM, Zou Y, Park S, Xu Z, Nakayama K, et al. Inhibition of FOXO3 tumor suppressor function by βTrCP1 through ubiquitin-mediated degradation in a tumor mouse model. PLoS ONE. 2010;5:e11171. https://doi.org/10.1371/journal.pone.0011171 .
doi: 10.1371/journal.pone.0011171 pubmed: 20625400 pmcid: 2896402
Zhao Y, Xiong X, Sun Y. DEPTOR, an mTOR inhibitor, is a physiological substrate of SCF
pubmed: 22017876 pmcid: 3216641 doi: 10.1016/j.molcel.2011.08.029
Zhang X, Cai J, Zheng Z, Polin L, Lin Z, Dandekar A, et al. A novel ER-microtubule-binding protein, ERLIN2, stabilizes Cyclin B1 and regulates cell cycle progression. Cell Disco. 2015;1:15024. https://doi.org/10.1038/celldisc.2015.24.
doi: 10.1038/celldisc.2015.24.
Das-Bradoo S, Ricke RM, Bielinsky AK. Interaction between PCNA and diubiquitinated Mcm10 is essential for cell growth in budding yeast. Mol Cell Biol. 2006;26:4806–17.
pubmed: 16782870 pmcid: 1489165 doi: 10.1128/MCB.02062-05
Amerik AY, Hochstrasser M. Mechanism and function of deubiquitinating enzymes. Biochim Biophys Acta. 2004;1695:189–207.
pubmed: 15571815 doi: 10.1016/j.bbamcr.2004.10.003
Park J, Cho J, Kim EE, Song EJ. Deubiquitinating enzymes: a critical regulator of mitosis. Int J Mol Sci. 2019;20:5997. https://doi.org/10.3390/ijms20235997.
doi: 10.3390/ijms20235997. pmcid: 6929034
Pfoh R, Lacdao IK, Saridakis V. Deubiquitinases and the new therapeutic opportunities offered to cancer. Endocr Relat Cancer. 2015;22:T35–54.
pubmed: 25605410 pmcid: 4304536 doi: 10.1530/ERC-14-0516
Tang Z, Shu H, Oncel D, Chen S, Yu H. Phosphorylation of Cdc20 by Bub1 provides a catalytic mechanism for APC/C inhibition by the spindle checkpoint. Mol Cell. 2004;16:387–97.
pubmed: 15525512 doi: 10.1016/j.molcel.2004.09.031
Hall MC, Warren EN, Borchers CH. Multi kinase phosphorylation of the APC/C activator Cdh1 revealed by mass spectrometry. Cell Cycle. 2004;3:1278–84.
pubmed: 15467459 doi: 10.4161/cc.3.10.1153
Clijsters L, Ogink J, Wolthuis R. The spindle checkpoint, APC/C
pubmed: 23775192 pmcid: 3691463 doi: 10.1083/jcb.201211019
Hoeller D, Dikic I. Targeting the ubiquitin system in cancer therapy. Nature. 2009;458:438–44.
pubmed: 19325623 doi: 10.1038/nature07960
Huang X, Dixit VM. Drugging the undruggables: exploring the ubiquitin system for drug development. Cell Res. 2016;26:484–98.
pubmed: 27002218 pmcid: 4822129 doi: 10.1038/cr.2016.31
Walczak H, Iwai K, Dikic I. Generation and physiological roles of linear ubiquitin chains. BMC Biol. 2012;10:23. https://doi.org/10.1186/1741-7007-10-23.
doi: 10.1186/1741-7007-10-23. pubmed: 22420778 pmcid: 3305636
Wu-Baer F, Ludwig T, Baer R. The UBXN1 protein associates with autoubiquitinated forms of the BRCA1 tumor suppressor and inhibits its enzymatic function. Mol Cell Biol. 2010;30:2787–98.
pubmed: 20351172 pmcid: 2876507 doi: 10.1128/MCB.01056-09
Durcan TM, Tang MY, Pérusse JR, Dashti EA, Aguileta MA, McLelland GL, et al. USP8 regulates mitophagy by removing K6-linked ubiquitin conjugates from parkin. EMBO J. 2014;33:2473–91.
pubmed: 25216678 pmcid: 4283406 doi: 10.15252/embj.201489729
Locke M, Toth JI, Petroski MD. Lys11- and Lys48-linked ubiquitin chains interact with p97 during endoplasmic-reticulum-associated degradation. Biochem J. 2014;459:205–16.
pubmed: 24417208 doi: 10.1042/BJ20120662
Nucifora FC Jr, Nucifora LG, Ng CH, Arbez N, Guo Y, Roby E, et al. Ubiqutination via K27 and K29 chains signals aggregation and neuronal protection of LRRK2 by WSB1. Nat Commun. 2016;7:11792. https://doi.org/10.1038/ncomms11792.
doi: 10.1038/ncomms11792. pubmed: 27273569 pmcid: 4899630
Palicharla VR, Maddika S. HACE1 mediated K27 ubiquitin linkage leads to YB-1 protein secretion. Cell Signal. 2015;27:2355–62.
pubmed: 26343856 doi: 10.1016/j.cellsig.2015.09.001
Chastagner P, Israël A, Brou C. Itch/AIP4 mediates Deltex degradation through the formation of K29-linked polyubiquitin chains. EMBO Rep. 2006;7:1147–53.
pubmed: 17028573 pmcid: 1679774 doi: 10.1038/sj.embor.7400822
Al-Hakim AK, Zagorska A, Chapman L, Deak M, Peggie M, Alessi DR. Control of AMPK-related kinases by USP9X and atypical Lys(29)/Lys(33)-linked polyubiquitin chains. Biochem J. 2008;411:249–60.
pubmed: 18254724 doi: 10.1042/BJ20080067
Yuan WC, Li YR, Lin SY, Chang LY, Tan YP, Hung CC, et al. K33-linked polyubiquitination of coronin 7 by Cul3-KLHL20 ubiquitin E3 ligase regulates protein trafficking. Mol Cell. 2014;54:596–600.
doi: 10.1016/j.molcel.2014.03.035
Huang H, Jeon MS, Liao L, Yang C, Elly C, Yates JR 3rd, et al. K33-linked polyubiquitination of T cell receptor-zeta regulates proteolysis-independent T cell signaling. Immunity. 2010;33:60–70.
pubmed: 20637659 pmcid: 2927827 doi: 10.1016/j.immuni.2010.07.002
Liu Z, Dong X, Yi HW, Yang J, Gong Z, Wang Y, et al. Structural basis for the recognition of K48-linked Ub chain by proteasomal receptor Rpn13. Cell Discov. 2019;5. https://doi.org/10.1038/s41421-019-0089-7 .
Zhang L, Xu M, Scotti E, Chen ZJ, Tontonoz P. Both K63 and K48 ubiquitin linkages signal lysosomal degradation of the LDL receptor. J Lipid Res. 2013;54:1410–20.
pubmed: 23419260 pmcid: 3653405 doi: 10.1194/jlr.M035774
Ohtake F, Tsuchiya H, Saeki Y, Tanaka K. K63 ubiquitylation triggers proteasomal degradation by seeding branched ubiquitin chains. Proc Natl Acad Sci USA. 2018;115:E1401–8.
pubmed: 29378950 doi: 10.1073/pnas.1716673115 pmcid: 5816176
Yang WL, Zhang X, Lin HK. Emerging role of Lys-63 ubiquitination in protein kinase and phosphatase activation and cancer development. Oncogene. 2010;29:4493–503.
pubmed: 20531303 pmcid: 3008764 doi: 10.1038/onc.2010.190
Erpapazoglou Z, Walker O, Haguenauer-Tsapis R. Versatile roles of k63-linked ubiquitin chains in trafficking. Cells. 2014;3:1027–88.
pubmed: 25396681 pmcid: 4276913 doi: 10.3390/cells3041027
Lauwers E, Jacob C, André B. K63-linked ubiquitin chains as a specific signal for protein sorting into the multivesicular body pathway. J Cell Biol. 2009;185:493–502.
pubmed: 19398763 pmcid: 2700384 doi: 10.1083/jcb.200810114
Taguchi SI, Honda K, Sugiura K, Yamaguchi A, Furukawa K, Urano T. Degradation of human Aurora-A protein kinase is mediated by hCdh1. FEBS Lett. 2002;519:59–65.
pubmed: 12023018 doi: 10.1016/S0014-5793(02)02711-4
Lindon C, Pines J. Ordered proteolysis in anaphase inactivates Plk1 to contribute to proper mitotic exit in human cells. J Cell Biol. 2004;164:233–41.
pubmed: 14734534 pmcid: 2172335 doi: 10.1083/jcb.200309035
Laoukili J, Alvarez-Fernandez M, Stahl M, Medema RH. FoxM1 is degraded at mitotic exit in a Cdh1-dependent manner. Cell Cycle. 2008;7:2720–6.
pubmed: 18758239 doi: 10.4161/cc.7.17.6580
Wei W, Jin J, Schlisio S, Harper JW, Kaelin WG Jr. The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell. 2005;8:25–33.
pubmed: 16023596 doi: 10.1016/j.ccr.2005.06.005

Auteurs

Fabin Dang (F)

Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.

Li Nie (L)

Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
State Key Laboratory for Quality and Safety of Agro-products, School of Marine Sciences, Ningbo University, Ningbo, 315211, China.

Wenyi Wei (W)

Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA. wwei2@bidmc.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH